Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Stock Information for Evogene Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evogene Ltd.

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag(TM) Capabilities
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI(TM) Toward Autonomous Small Molecule Discovery and Optimization
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Evogene Reports First Quarter 2026 Financial Results
Evogene to Present at the 24th Schrödinger European User Group Meeting
Evogene Schedules First Quarter 2026 Financial Results Release

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.